for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cardiovascular Systems Inc

CSII.OQ

Latest Trade

49.92USD

Change

-0.96(-1.89%)

Volume

85,837

Today's Range

49.89

 - 

51.30

52 Week Range

24.89

 - 

52.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
50.88
Open
50.97
Volume
85,837
3M AVG Volume
6.36
Today's High
51.30
Today's Low
49.89
52 Week High
52.45
52 Week Low
24.89
Shares Out (MIL)
35.27
Market Cap (MIL)
1,794.44
Forward P/E
4,348.72
Dividend (Yield %)
--

Next Event

Cardiovascular Systems Product Portfolio Update - Call

Latest Developments

More

Cardiovascular Systems Q4 Earnings Per Share $0.04

Cardiovascular Systems Inc Acquires Gardia Medical's Wirion Embolic Protection System

Cardiovascular Systems Q3 Earnings Per Share $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cardiovascular Systems Inc

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Industry

Medical Equipment & Supplies

Contact Info

1225 Old Highway 8 NW

+1.651.2591600

http://csi360.com/

Executive Leadership

Scott R. Ward

Chairman of the Board, President, Chief Executive Officer

Jeffrey S. Points

Chief Financial Officer

Rhonda J. Robb

Chief Operating Officer

Sandra Marie Sedo

Chief Compliance Officer

Alexander Rosenstein

General Counsel and Corporate Secretary

Key Stats

2.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2017

-0.060

2018

0.050

2019

-0.010

2020(E)

0.012
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.24
Price To Book (MRQ)
12.01
Price To Cash Flow (TTM)
562.34
Total Debt To Equity (MRQ)
14.18
LT Debt To Equity (MRQ)
14.18
Return on Investment (TTM)
-0.15
Return on Equity (TTM)
-0.12

Latest News

BRIEF-Cardiovascular Systems Inc Q3 Earnings Per Share $0.01

* CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Cardiovascular Systems Says OrbusNeich 1.0mm Sapphire II PRO Coronary Balloon Granted FDA Clearance

* CARDIOVASCULAR SYSTEMS, INC. AND ORBUSNEICH ANNOUNCE FDA CLEARANCE OF THE FIRST AND ONLY 1.0MM CORONARY BALLOON IN THE U.S.

BRIEF-Cardiovascular Systems Q2 Loss Per Share $0.01

* CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS

BRIEF-Cardiovascular Systems Appoints Jeff Points As CFO

* CARDIOVASCULAR SYSTEMS, INC. APPOINTS JEFF POINTS AS CHIEF FINANCIAL OFFICER

BRIEF-Cardiovascular Systems Inc reports Q1 loss per share $0.06

* Cardiovascular Systems Inc reports fiscal 2018 first-quarter financial results

BRIEF-Cardiovascular Systems announces anticipated revenue impact from hurricanes

* Cardiovascular Systems announces anticipated revenue impact from hurricanes Harvey and Irma

BRIEF-Cardiovascular Systems Q4 earnings per share $0.02

* Cardiovascular Systems, Inc. Reports fiscal 2017 fourth-quarter financial results

BRIEF-Brown Capital Management LLC reports 7.56 pct passive stake in Cardiovascular Systems

* Brown Capital Management LLC reports 7.56 percent passive stake in Cardiovascular Systems Inc as of June 30 - sec filing Source text : http://bit.ly/2u638Ru Further company coverage:

BRIEF-Cardiovascular Systems says on June 27, Plaintiffs filed an amended complaint regarding Shoemaker V. Cardiovascular Systems case

* Cardiovascular Systems - On June 27, 2017, Plaintiffs filed an amended complaint regarding Shoemaker V. Cardiovascular Systems case

BRIEF-Cardiovascular Systems Q3 loss per share $0.05

* Cardiovascular Systems Inc reports fiscal 2017 third-quarter financial results

BRIEF-Cardiovascular Systems updates on former employee case

* Cardiovascular Systems says jury awarded plaintiff $2.7 million compensatory damages for claims for whistleblower retaliation, wrongful termination

BRIEF-Cardiovascular Systems receives approval for Diamondback 360 coronary orbital atherectomy system Micro Crown in the United States

* Cardiovascular Systems, Inc. receives approval for the Diamondback 360® coronary orbital atherectomy system (oas) micro crown in the United States

BRIEF-Cardiovascular Systems says Martha Goldberg Aronson joins board

* Cardiovascular systems announces healthcare veteran Martha Goldberg Aronson joins board of directors Source text for Eikon: Further company coverage:

BRIEF-Cardiovascular Systems reports Q2 earnings per share $0.03

* Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S

BRIEF-Cardiovascular Systems says a stockholder derivative action was filed in United States district court against Co

* Cardiovascular systems -on may 10, 2016, a stockholder derivative action was filed in united states district court for district of minnesota against co

BRIEF-Cardiovascular Systems Inc signs distribution agreement with Medikit Co., Ltd

* Press release - Cardiovascular systems, Inc. signs distribution agreement with Medikit Co., Ltd. for Japan Source text for Eikon: Further company coverage:

BRIEF-Medikit gets exclusive distribution right of calcific lesions treatment device from CSI

* Says it reaches agreement with Cardiovascular Systems Inc , and gets exclusive distribution right of calcific lesions treatment device Diamondback360 produced by Cardiovascular Systems, in Japan market

BRIEF-Cardiovascular Systems Q1 loss per share $0.06

* Cardiovascular systems, Inc. reports fiscal 2017 first-quarter financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up